The Technical Analyst
Sana Biotechnology, Inc. [SANA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Sana Biotechnology, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
2.59% $8.72
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 922.31 mill |
| EPS: | -1.460 |
| P/E: | -5.97 |
| Earnings Date: | May 06, 2024 |
| SharesOutstanding: | 220.45 mill |
| Avg Daily Volume: | 2.01 mill |
| RATING 2024-04-26 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.97 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.02x |
| Company: PE -5.97 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.171 (-98.04%) $-8.55 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 7.99 - 9.45 ( +/- 8.37%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-05 | Bishop Hans Edgar | Buy | 2 774 | Common Stock |
| 2024-04-01 | Fmr Llc | Buy | 0 | Common Stock |
| 2024-03-08 | Yang Patrick Y | Sell | 25 000 | Common Stock |
| 2024-03-07 | Williams Douglas E | Buy | 301 875 | Stock Option (Right to Buy) |
| 2024-03-07 | Williams Douglas E | Buy | 67 083 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 6.22 |
| Last 97 transactions |
| Buy: 15 455 910 | Sell: 11 982 863 |
Forecast:
16:00 - $8.72
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.72
Forecast 2: 16:00 - $8.72
Forecast 3: 16:00 - $8.72
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.72 (2.59% ) |
| Volume | 1.588 mill |
| Avg. Vol. | 2.01 mill |
| % of Avg. Vol | 78.94 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SANA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $6.13 | N/A | Active |
|---|
SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Latest Press Releases
2024-02-29 16:05:00 - Press Release
Sana Biotechnology Reports Fourth Quarter And Full Year 2023 Financial Results And Business Updates
Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, b-cell mediated autoimmune diseases, and type 1 diabetes
2024-02-28 16:05:00 - Press Release
Sana Biotechnology To Present At The Cowen 44th Annual Health Care Conference
Seattle, feb. 28, 2024 (globe newswire) -- sana biotechnology, inc. (nasdaq: sana), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the cowen 44th annual health care conference at 2:50 p.m. et on wednesday, march 6, 2024. the presentation will feature a business overview and update by steve harr, sana's president and chief executive officer.
2024-02-13 16:05:00 - Press Release
Sana Biotechnology Announces Publication Of Preclinical Diabetes Data In Cell Stem Cell Demonstrating Insulin Independence Following Transplantation Of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression In A Diabetic Nhp
Transplant of hip-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (nhp), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration
2024-02-12 16:05:00 - Press Release
Sana Biotechnology Announces Closing Of Upsized Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
Seattle, feb. 12, 2024 (globe newswire) -- sana biotechnology, inc. (nasdaq: sana), a company focused on changing the possible for patients through engineered cells, today announced that it has closed its underwritten upsized public offering of 21,772,728 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 4,500,000 additional shares of its common stock, at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of its common stock at a price to the public of $5.4999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0...
2024-02-08 01:22:00 - Press Release
Sana Biotechnology Announces Pricing Of Upsized Public Offering
Seattle, feb. 08, 2024 (globe newswire) -- sana biotechnology, inc. (nasdaq: sana), a company focused on changing the possible for patients through engineered cells, today announced that it has priced its underwritten upsized public offering of 17,272,728 shares of its common stock at a price to the public of $5.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 12,727,272 shares of common stock at a price to the public of $5.4999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.0001 per share exercise price for each pre-funded warrant. all of the shares and pre-funded warrants are to be sold by sana...
Latest News
2024-02-18 11:20:54 - 24/7 Wall Street
Insider Buying: Taking a Controlling Stake in a Struggling Retailer?
The biggest insider trading news of the week may have been Amazon.com Inc. (NASDAQ: AMZN) founder Jeff Bezos shedding over $4 billion worth of the company's shares as he reportedly prepares to move to Florida to take advantage of the better income tax environment.
2024-01-17 14:00:00 - Seeking Alpha
JD Henning Cautious About 2024, An Unusual Year For Market Considerations
JD Henning discusses his approach to the market and emphasizes the importance of timing and using momentum gauges to avoid major market downturns. Investing vs trading portfolios.
2024-01-05 15:13:56 - Seeking Alpha
Sana Biotechnology: SC291 Moving Forward Beyond Hematological Malignancies
Additional results from a Sana Biotechnology, Inc. phase 1 study, using SC291 for the treatment of patients with B-cell lymphomas and leukemias, are expected in 2024. Initial results from phase 1 study, using SC291 for the treatment of patients with autoimmune disorders, expected in 2024. Initial results from phase 1 study, using SC262 for the treatment of patients with r/r B-cell Lymphomas who failed prior anti-CD19 therapies, expected in 2024.
2024-01-03 16:05:00 - GlobeNewsWire
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SEATTLE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference at 9:45 a.m. PT on Tuesday, January 9, 2024. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
2023-11-21 09:00:00 - GlobeNewsWire
Sana Biotechnology to Present at November and December 2023 Investor Conferences
SEATTLE, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in November and December. The presentations will feature a business overview and update.
2023-08-30 16:05:00 - GlobeNewsWire
Sana Biotechnology to Present at September 2023 Investor Conferences
SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at five investor conferences in September. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer, and Nate Hardy, Sana's Chief Financial Officer.
2023-07-09 10:09:57 - Seeking Alpha
Sana Biotechnology: Hypoimmune Platform Might Stealth Cells
Results from the phase 1 study using SC291 for the treatment of patients with B-cell lymphomas are expected to be released later in 2023. It is said that the global B-cell lymphoma treatment market could reach $13.14 billion by 2030. The company is testing the use of its hypoimmune platform, which might be capable of providing long-term durable responses, without immunosuppression being needed.
2023-05-31 16:05:00 - GlobeNewsWire
Sana Biotechnology to Present at June 2023 Investor Conferences
SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.
2023-05-04 13:56:05 - InvestorPlace
7 High-Potential Penny Stocks in the Biotech Sector
Most of the biggest biotech stocks on the market started off as unknown penny stocks. Look at Axsome Therapeutics (NASDAQ: AXSM ), for example.
2023-05-03 16:05:00 - GlobeNewsWire
Sana Biotechnology to Present at May 2023 Investor Conferences
SEATTLE, May 03, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in May. The presentations will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer and Nate Hardy, Sana's Chief Financial Officer.